Doktor axborotnomasi 2024, №2 (114)

Maqola mavzusi

ПРИНЦИПЫ ДИАГНОСТИКИ АУТОИММУННОЙ ГЕМОЛИТИЧЕСКОЙ АНЕМИИ (154-158)

Mualliflar

Д. А. Мадарипова

Muassasa

Бухарский государственный медицинский институт, Бухара, Узбекистан

Annotatsiya

Диагноз аутоиммунной гемолитической анемии (АИГА) можно поставить с помощью поэтапного под хода, направленного на выявление лабораторных и клинических признаков гемолиза, а затем определить им мунную природу гемолиза прямым путем антиглобулинового теста. Как только исключаются альтернативные причин этих результатов, устанавливается АИГА и необходимо искать вторичные причины, а также выявить тип АИГА. Цель исследования: изучить как можно диагностировать АИГА и его подтипы путем сочетания клинической оценки и лабораторных исследований.

Kalit so'zlar

аутоиммунная гемолитическая анемия, болезни холодовых агглютининов, гемолиз, анти глобулиновый тест.

Adabiyotlar

1. Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320-330. 2. Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid mono therapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163(3):393-399. 3. Broome C, Cunningham JM, Mullins M, et al. Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort. Blood. 2017;130(suppl 1):928. 4. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res (Hoboken). 2017;69(8):1095-1110. 5. Compston J, Cooper A, Cooper C, et al; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43. 6. Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory, and fatal primary autoimmune hemo lytic anemias. Am J Hematol. 2015;90(8):E149-E151. 7. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985 4996, quiz 5105. 8. Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3): 395-411. 9. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A; British Society for Haematology Guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-220. 10. Kulpa J, Skrabs C, Simanek R, et al. Probability of remaining in unsustained complete remission after steroid ther apy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia. Wien Klin Woch enschr. 2016;128(7-8):234-237. 11. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic ane mia: analysis of 109 cases. Blood. 1987;69(3):820-826. 12. Milkins C, Berryman J, Cantwell C, et al; British Committee for Standards in Haematology. Guidelines for pre transfusion compatibility pro cedures in blood transfusion laboratories. Transfus Med. 2013;23(1):3-35. 13. Molica S, Polliack A. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leuk Res. 2016;50:31-36. 14. Montillo M, O‘Brien S, Tedeschi A, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017;7(2):e524. 15. Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia inadults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89(9): E150-E155. 16. Tjønnfjord E, Vengen OA, Berentsen S, Tjønnfjord GE. Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease. BMJ Case Rep. 2017;2017:bcr-2016-219066. 17. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244-249. 18. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One. 2012;7(3):e33442.